{
  "created_at": "Sat Mar 05 18:33:39 +0000 2022",
  "id_str": "1499912642403655683",
  "full_text": "U.S. drug regulators approved a new customized, cell-based treatment for blood cancer from Johnson &amp; Johnson that is the first such therapy in the U.S. to be developed initially in China https://t.co/sJTmbUumgM",
  "display_text_range": [
    0,
    214
  ],
  "entities": {
    "hashtags": [],
    "symbols": [],
    "user_mentions": [],
    "urls": [
      {
        "url": "https://t.co/sJTmbUumgM",
        "expanded_url": "https://on.wsj.com/3IFb53E",
        "display_url": "on.wsj.com/3IFb53E",
        "indices": [
          191,
          214
        ]
      }
    ]
  },
  "user": {
    "name": "The Wall Street Journal",
    "screen_name": "WSJ",
    "profile_image_url_https": "https://pbs.twimg.com/profile_images/971415515754266624/zCX0q9d5_normal.jpg"
  },
  "retweet_count": 35,
  "favorite_count": 81,
  "possibly_sensitive": false,
  "original_created_at": "Sat Mar 05 01:00:15 +0000 2022",
  "localize": [
    {
      "locale": "ja",
      "full_text": "米国医薬品規制当局が、ジョンソン・エンド・ジョンソンの血液がんに対する新しいカスタマイズされた細胞ベースの治療法を承認。この治療法は、米国で初めて中国で初期開発されたものです。https://t.co/sJTmbUumgM"
    },
    {
      "locale": "zh",
      "full_text": "美国药品监管机构批准了强生公司（Johnson &amp; Johnson）的一种新的定制化、基于细胞的血癌治疗方法，这是美国第一个在中国初步开发的此类疗法https://t.co/sJTmbUumgM。"
    },
    {
      "locale": "zh-Hant",
      "full_text": "美國藥品監管機構批准了強生公司（Johnson &amp; Johnson）的一種新的定製化、基於細胞的血癌治療方法，這是美國第一個在中國初步開發的此類療法https://t.co/sJTmbUumgM。"
    }
  ]
}